- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | VENUS MEDTECH-B (02500): ANNOUNCEMENT MADE PURSUANT TO RULE 13.10 OF THE LISTING RULES | 1 | HKEx | ||
| 29.12.25 | VENUS MEDTECH-B (02500): DISCLOSEABLE TRANSACTION IN RELATION TO DISPOSAL OF SHARES OF AN INVESTEE COMPANY | 1 | HKEx | ||
| VENUS MEDTECH Aktie jetzt für 0€ handeln | |||||
| 24.12.25 | VENUS MEDTECH-B (02500): VOLUNTARY ANNOUNCEMENT SUBMISSION OF CE MDR MARKING APPLICATION FOR THE CARDIOVALVE TRICUSPID VALVE REPLACEMENT | 2 | HKEx | ||
| 28.11.25 | VENUS MEDTECH-B (02500): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 19.11.25 | VENUS MEDTECH-B (02500): VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE | 1 | HKEx | ||
| 17.11.25 | Venus Medtech (Hangzhou) Inc.: Cardiovalve Submits CE File for Approval Following Successful TARGET Study Completion | 297 | PR Newswire | Exciting Data on Cardiovalve Tricuspid Valve Replacement Device Presented at PCR London Valves 2025 meeting.
LONDON, Nov. 17, 2025 /PRNewswire/ -- Venus Medtech... ► Artikel lesen | |
| 14.11.25 | VENUS MEDTECH-B (02500): SUPPLEMENTAL ANNOUNCEMENT PROPOSED ISSUE OF CONVERTIBLE BONDS UNDER GENERAL MANDATE AND ENTRY INTO THE SUPPLEMENTAL AGREEMENTS | - | HKEx | ||
| 12.11.25 | VENUS MEDTECH-B (02500): PROXY FORM FOR USE AT THE EGM | - | HKEx | ||
| 12.11.25 | VENUS MEDTECH-B (02500): NOTICE OF EXTRAORDINARY GENERAL MEETING | 3 | HKEx | ||
| 12.11.25 | VENUS MEDTECH-B (02500): (1) MAJOR TRANSACTION IN RELATION TO DISPOSAL OF PROPERTY AND (2) NOTICE OF EXTRAORDINARY GENERAL MEETING | 3 | HKEx | ||
| 12.11.25 | BRIEF: Venus Medtech sells Hangzhou project for 375 million yuan | 2 | Bamboo Works | ||
| 11.11.25 | VENUS MEDTECH-B (02500): MAJOR TRANSACTION IN RELATION TO DISPOSAL OF PROPERTY CLOSURE OF REGISTER OF MEMBERS AND CHANGE IN USE OF PROCEEDS FROM THE INITIAL ... | 1 | HKEx | ||
| 27.10.25 | Venus Medtech's Cardiovalve completes enrollment in tricuspid valve replacement trial | 1 | MassDevice | ||
| 25.10.25 | Venus Medtech (Hangzhou) Inc.: Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement | 662 | PR Newswire | The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch
HANGZHOU, China, Oct. 25, 2025 /PRNewswire/... ► Artikel lesen | |
| 24.10.25 | VENUS MEDTECH-B (02500): VOLUNTARY ANNOUNCEMENT COMPLETION OF FULL PATIENT ENROLLMENT FOR CONFIRMATORY CLINICAL STUDY OF CARDIOVALVE TTVR | - | HKEx | ||
| 29.09.25 | VENUS MEDTECH-B (02500): 2025 INTERIM REPORT | 1 | HKEx | ||
| 28.08.25 | VENUS MEDTECH-B (02500): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2025 | - | HKEx | ||
| 18.08.25 | VENUS MEDTECH-B (02500): DATE OF BOARD MEETING | 1 | HKEx | ||
| 05.08.25 | Venus Medtech (Hangzhou) Inc.: Court Sides with Cardiovalve in Edwards patent spat | 252 | PR Newswire | HANGZHOU, China, Aug. 5, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. ("Venus Medtech", Stock Code: 02500.HK) recently announced a decisive legal victory for its wholly-owned subsidiary... ► Artikel lesen | |
| 22.04.25 | Venus Medtech (Hangzhou) Inc.: Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations | 540 | PR Newswire | HONG KONG, April 22, 2025 /PRNewswire/ -- Venus MedTech (Hangzhou) Inc. (Stock Code: 2500.HK, hereinafter referred to as "Venus Medtech" or the "Company"), a global leader in structural heart... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PAVMED | 11,970 | 0,00 % | Should you chase the rally in PAVmed stock after it quadrupled on Wednesday? | ||
| SIEMENS HEALTHINEERS | 43,630 | -2,00 % | ANALYSE-FLASH: UBS hebt Ziel für Siemens Healthineers auf 51 Euro - 'Neutral' | ZÜRICH (dpa-AFX Broker) - Die Schweizer Großbank UBS hat das Kursziel für Siemens Healthineers von 50 auf 51 Euro angehoben, aber die Einstufung auf "Neutral" belassen. Die Aktien der Bayern seien... ► Artikel lesen | |
| FRESENIUS | 47,640 | +1,10 % | ROUNDUP/Aktien Frankfurt Schluss: Kleines Dax-Plus - Chip-Ausrüster gesucht | FRANKFURT (dpa-AFX) - Optimistische Wachstumsprognosen des taiwanesischen Chip-Giganten TSMC haben den Aktien deutscher Zulieferer für die Chip-Industrie am Donnerstag kräftig Aufwind verliehen. Ansonsten... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 36,630 | +1,81 % | Elmos, FMC, Gerresheimer, Hensoldt, Hypoport, Zalando: Neue Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 35,200 | -0,73 % | Goldman setzt den Rotstift an: Carl Zeiss Meditec im Kurskeller: Analysten senken Kursziel drastisch | © Foto: Foto: ZEISSGoldman Sachs senkt das Kursziel für Carl Zeiss Meditec von 54 auf 42 Euro und stuft die Aktie auf "Neutral" herab. Ein schwaches erstes Quartal und strukturelle Probleme belasten... ► Artikel lesen | |
| HEARTFLOW | 33,550 | -1,87 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| ANTERIS TECHNOLOGIES GLOBAL | 6,060 | 0,00 % | Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic |
MINNEAPOLIS and BRISBANE, Australia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ: AVR, ASX: AVR), a global structural heart company committed... ► Artikel lesen | |
| GENEDX | 100,04 | +0,36 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| PROGYNY | 25,450 | +0,28 % | Forecasting The Future: 6 Analyst Projections For Progyny | ||
| PRIVIA HEALTH GROUP | 23,600 | +1,68 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| RXSIGHT | 9,950 | 0,00 % | Expert Outlook: RxSight Through The Eyes Of 5 Analysts | ||
| BRIGHTSPRING HEALTH SERVICES | 39,210 | +1,24 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 23,300 | 0,00 % | Alignment Healthcare Named to the 2026 Fortune World's Most Admired Companies List for First Time | ||
| PROCEPT BIOROBOTICS | 30,940 | +2,08 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| UNITEDHEALTH | 297,40 | -0,07 % | Judge Tosses Drug Pricing Conspiracy Case Against CVS, UnitedHealth, Evernorth |
Das Unternehmen VENUS MEDTECH HANGZHOU INC kann der Branche Gesundheitswesen zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VENUS MEDTECH HANGZHOU INC finden Sie auf Wallstreet Online.